NYSEAMERICAN : ARMP
Armata Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 3.44 USD (Oct 30, 2026, 9:30 AM EDT) · Market cap 127.91M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 121.96M |
| Enterprise Value | 411.96M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 37.18M |
| Shares Outstanding | 37.18M |
| Shares Change (YoY) | +0.77% |
| Shares Change (QoQ) | +69.84% |
| Owned by Insiders (%) | 0.55% |
| Owned by Institutions (%) | 13.52% |
| Float | 11.90M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 22.00 |
| Forward PS | 126.38 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 74.32 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.11 |
| Quick Ratio | 0.11 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.65 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -25.83% |
| Return on Invested Capital (ROIC) | -28.05% |
| Return on Capital Employed (ROCE) | 22.02% |
| Weighted Average Cost of Capital (WACC) | 7.23% |
| Revenue Per Employee | $90,869 |
| Profits Per Employee | -$3.15M |
| Employee Count | 61 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.41 |
| 52-Week Price Change | -39.93% |
| 50-Day Moving Average | 4.18 |
| 200-Day Moving Average | 7.01 |
| Relative Strength Index (RSI) | 43.84 |
| Average Volume (20 Days) | 98,908 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 899,639 |
| Short Previous Month | 963,383 |
| Short % of Shares Out | 2.42% |
| Short % of Float | 7.56% |
| Short Ratio (days to cover) | 5.78 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 5.54M |
| Gross Profit | -12.05M |
| Operating Income | -35.28M |
| Pretax Income | -192.18M |
| Net Income | -192.18M |
| EBITDA | -33.45M |
| EBIT | -35.28M |
| Loss Per Share | -$5.27 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 23.95M |
| Total Debt | 313.95M |
| Net Cash | -290.00M |
| Net Cash Per Share | -$7.80 |
| Equity (Book Value) | -231.17M |
| Book Value Per Share | -6.22 |
| Working Capital | -223.04M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -25.42M |
| Capital Expenditures | -374,000 |
| Depreciation & Amortization | 1.84M |
| Net Borrowing | 40.00M |
| Free Cash Flow | -25.79M |
| FCF Per Share | -$0.69 |
Margins
| Measure | Value |
|---|
| Gross Margin | -217.36% |
| Operating Margin | -636.55% |
| Pretax Margin | -3,467.04% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.77% |
| Shareholder Yield | -0.77% |
| Earnings Yield | -160.69% |
| FCF Yield | -21.15% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $17.50 |
| Price Target Difference | 433.54% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -12.22 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |